Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ivacaftor

Reshma Kewalramani joins Vertex Pharmaceuticals as CMO

She will succeed Jeffrey Chodakewitz

- PMLiVE

Merck and Pfizer set to win NICE backing for Bavencio

The PD-L1 inhibitor is being assessed for the treatment of mMCC patients

- PMLiVE

The challenges of making genomics a reality for patients today, not tomorrow

Creating transformative medicines

EISAI

NICE reverses its rejection of Eisai’s Lenvima

The cost-effectiveness watchdog has now backed the thyroid cancer treatment

- PMLiVE

Vertex’s two-drug cystic fibrosis treatment cleared in US

FDA approves Symdeko, which combines Kalydeco and tezacaftor

Roche Basel Switzerland

NICE backs Roche’s Gazyvaro after initial rejection

An undisclosed discount swayed the cost-effectiveness body

- PMLiVE

Roche’s lung drug Esbriet reserved for worse cases, says NICE

Boehringer Ingelheim’s Ofev subject to same conditions

- PMLiVE

NICE backs trial of online and mobile depression programme

First digital psychological therapy briefing covers Servier and Gaia's Deprexis

Biogen Idec building

NICE finally starts review of Biogen’s Spinraza for SMA

Will evaluate the treatment based on its Single Technology Appraisal process

- PMLiVE

Unsure on efficacy, NICE passes J&J’s Darzalex to CDF

The bone marrow cancer therapy is now temporarily approved as a fourth-line treatment

- PMLiVE

Vertex’s Orkambi receives EU green light for licence extension

Becomes first medicine to treat the underlying cause of CF in children

- PMLiVE

NICE backs GSK’s €594k gene therapy for rare disease

The treatment offers 'bubble baby' patients an alternative to a stem cell transplant

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links